Laboratory Investigation

Kidney International (1994) 45, 794–802; doi:10.1038/ki.1994.105

Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats

Kohei Uriu1, Kazo Kaizu1, Osamu Hashimoto1, Norikuni Komine1 and Sumiya Etoh1

1Kidney Center and First Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine, Kitakyusyu, Fukuoka, Japan

Correspondence: Kazo Kaizu MD, Kidnay Center, UOEH, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyusyu, 807, Japan.

Received 26 December 1991; Revised 15 October 1993; Accepted 18 October 1993.

Top

Abstract

Acute and chronic effects of thromboxane A2 inhibition on the renal hemodynamics in streptozotocin-induced diabetic rats. We examined acute and chronic effects of thromboxane (TX) A2 inhibition on the renal hemodynamics at early and late stage of untreated streptozotocin (STZ)-induced diabetic rats. Two weeks and 28 weeks after the induction of diabetes, renal blood flow (RBF) under anesthesia was measured with an electromagnetic flowmeter before and after TXA2 inhibition. In two-week-old diabetic rats, a specific TXA2 synthetase inhibitor, OKY-046, or a specific TXA2 receptor antagonist, Sulotroban, increased renal vascular resistance (RVR) and ameliorated the hyperperfusion. The renal vasoconstrictive effect of OKY-046 was blunted by an angiotensin converting enzyme (ACE) inhibitor, MK422, or an angiotensin II receptor antagonist, Saralasin. On the contrary, OKY-046 ameliorated the renal hypoperfusion by decreasing RVR in 28-week-old diabetic rats. Chronic oral administration of OKY-046 ameliorated not only the renal hyperperfusion but increased urinary albumin excretion (UAE) at two weeks, but also the renal hypoperfusion, filtration fraction and UAE at 24 weeks. It is suggested that TXA2 might, at least in part, play important roles in the hyperperfusion by modulating activity of the renin-angiotensin system at an early stage of untreated diabetic rats and in the hypoperfusion at the late stage of untreated diabetic rats, and that TXA2 is also involved in the increase of UAE. These results support roles for TXA2 in the progression of renal injury in STZ-induced diabetic rats.

Top

References

  1. Anderson S, Brenner BM: Pathogenesis of diabetic glomerulopathy: Hemodynamic considerations. Diabetes Metab Rev 4:163–177, 1988 | PubMed | ISI | ChemPort |
  2. O'donnell MP, Kasiske BL, Keane WF: Glomerular hemodynamic and structural alterations in experimental diabetes mellitus. FASEB J 2:2339–2347, 1988 | PubMed | ChemPort |
  3. Craven PA, Caines MA, DeRubertis FR: Sequential alterations in glomerular prostaglandin and thromboxane synthesis in diabetic rats: Relationship to the hyperfiltration of early diabetes. Metabolism 36:95–103, 1987 | Article | PubMed | ChemPort |
  4. Moel DI, Safirstein RL, McEvoy RC, Hsueh W: Effect of aspirin on experimental diabetic nephropathy. J Lab Clin Med 110:300–307, 1987 | PubMed | ISI | ChemPort |
  5. Schambelan M, Blake S: Increased prostaglandin production by glomeruli isolated from rats with streptozotocin-induced diabetes mellitus. J Clin Invest 75:404–412, 1985 | PubMed | ISI | ChemPort |
  6. Craven PA, DeRubertis FR: Role for local prostaglandin and thromboxane production in the regulation of glomerular filtration rate in the rat with streptozocin-induced diabetes. J Lab Clin Med 113:674–681, 1989 | PubMed | ISI | ChemPort |
  7. Esmatjes E, Fernandez MR, Halperin I, Camps J, Gaya J, Arroyo V, Rivera F, Figuerola D: Renal hemodynamic abnormalities in patients with short term insulin-dependent diabetes mellitus: role of renal prostaglandins. J Clin Endocrinol Metab 60:1231–1236, 1985
  8. Jensen PK, Steven K, Blaehr H, Christiansen JS, Parving HH: Effects of indomethacin on glomerular hemodynamics in experimental diabetes. Kidney Int 29:490–495, 1986 | PubMed | ISI | ChemPort |
  9. Kasiske BL, O'Donnell MP, Keane WF: Glucose-induced increases in renal hemodynamic function. Diabetes 34:360–364, 1985 | PubMed |
  10. Dunn MJ: Glomerular eicosanoids and diabetes mellitus. J Lab Clin Med 113:659–660, 1989
  11. Katayama S, Inaba M, Maruno Y, Omoto A, Kawazu S, Ishii J: Increased thromboxane B2 excretion in diabetes mellitus. J Lab Clin Med 109:711–717, 1987 | PubMed |
  12. Hora K, Oguchi H, Furukawa T, Hora K, Tokunaga S: Effects of a selective thromboxane synthetase inhibitor OKY-046 on experimental diabetic nephropathy. Nephron 56:297–305, 1990
  13. Bunke M, Itskovitz H: Urinary excretion and renal production of prostaglandins E2, F2alpha, and thromboxane B2 in experimental diabetes mellitus. J Lab Clin Med 108:332–339, 1986
  14. Craven PA, DeRubertis FR: Suppression of urinary albumin excretion in diabetic rats by 4' (imidazol-1-yl) acetophenon, a selective inhibitor of thromboxane synthesis. J Lab Clin Med 116:469–478, 1990
  15. Barnett AH, Leatherdale BA, Polak A, Toop M, Wakelin K, Britton JR, Bennett J, Rowe D: Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet i:1322–1324, 1984
  16. Esmatjes E, Conget JI, Gaya J, Fernandez MR, Ferrer JP, Rivera F, Vilardell E: Effects of thromboxane synthesis inhibitor Triflusal on renal hemodynamics in microalbuminuric diabetic patients. Diabetes Care 13:1114–1117, 1990
  17. Kaizu K, Marsh D, Zipser R, Glassock RJ: Role of prostaglandins and angiotensin II in experimental glomerulonephritis, Kidney Int 28:629–635, 1985
  18. Jensen PK, Christiansen S, Steven K, Parving H-H: Renal function in streptozotocin-diabetic rats. Diabetologia 21:409–414, 1981 | PubMed | ISI | ChemPort |
  19. Daniels BS, Hostetter TH: Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 38:981–986, 1989
  20. Mauer SM, Steffes MW, Azar S, Brown DM: Effects of sorbinil on glomerular structure and function in long-term diabetic rats. Diabetes 38:839–846, 1989
  21. Michels LD, O'Donell MP, Kean W: Glomerular hemodynamic and structural correlations in long-term experimental diabetic rats. J Lab Clin Med 103:840–847, 1984
  22. Zimmerman BG, Raich PC, Vavrek RJ, Stewart JM: Bradykinin contribution to renal blood flow effect of angiotensin converting enzyme inhibitor in conscious sodium-restricted dog. Circ Res 66:242–248, 1990
  23. Ortola FV, Ballermann BJ, Anderson S, Mendez RE, Brenner BM: Elevated plasma atrial natriuretic peptide levels in diabetic rats: Potential mediator of hyperfiltration. J Clin Invest 80:670–674, 1987 | PubMed | ISI | ChemPort |
  24. Perico N, Benigni A, Gabanelli M, Piccinelli A, Rog M, DeRive C, Remuzzi G: Atrial natriuretic peptide and prostacyclin synergistically mediate hyperfiltration and hyperperfusion of diabetic rats. Diabetes 41:533–538, 1992 | PubMed |
  25. Wilson TW, Tan LK: Low plasma renin activity in diabetes: Relation to urine prostaglandin excretion. Diabetes 34:145–150, 1985
  26. Welch W, Wilcox CS, Dunbar KR: Modulation of renin by thromboxane: Studies with thromboxane synthase inhibitor, receptor antagonists, and mimetic. Am J Physiol 257:F554–F560, 1989 | PubMed |
  27. Omoto A, Katayama S, Inaba M, Maruno Y, Watanabe T, Kawazu S, Ishii J: Effects of thromboxane A2 synthesis inhibition on renal renin release and protein excretion in diabetic rats. Jpn J Nephrol 30:305–311, 1988
  28. Stork JE, Rahman MA, Dunn MJ: Eicosanoids in exprimental and human renal disease. Am J Med 80(Suppl 1A):34–45, 1986 | Article | PubMed | ISI | ChemPort |
  29. Remuzzi G, FitzGerald GA, Patrono C: Thromboxane synthesis and action within the kidney. Kidney Int 41:1483–1493, 1992 | PubMed | ISI | ChemPort |
  30. Welch WJ, Wilcox CS: Feedback responses during sequential inhibition of angiotensin and thromboxane. Am J Physiol 258:F457–F466, 1990 | PubMed | ISI | ChemPort |
  31. Tucker BJ, Anderson CM, Thies RS, Collins RC, Blantz RC: Glomerular hemodynamic alterations during acute hyperinsulinemia in normal and diabetic rats. Kidney Int 42:1160–1168, 1992 | PubMed | ISI | ChemPort |
  32. Wilkes BM, Kaplan R, Mento PF, Aynedjian HS, Macica CM, Schlondroff D, Bank N: Reduced glomerular thromboxane receptor sites and vasoconstrictor responses in diabetic rats. Kidney Int 41:992–999, 1992
  33. Tucker BJ, Brault SM, Mendonca MM, Blantz RC: Mechanism of hyperinsulinemia induced renal vasoconstriction in poorly controlled chronic diabetic rats. (abstract) JASN 1(4):644, 1990
  34. Tucker BJ, Collins RC, Ziegler MG, Blantz RC: Dissociation between glomerular hyperfiltration and extracellular volume in diabetic rats. Kidney Int 39:1176–1183, 1991 | PubMed |
  35. Hashimoto Y, Ideura T, Yoshimura A, Koshikawa S: Auto-regulation of renal blood flow in streptozocin-induced diabetic rats. Diabetes 38:1109–1113, 1989 | PubMed | ISI | ChemPort |
  36. Bank N, Lahorra H, Aynedjian HS, Wilkes BM: Sodium restriction corrects hyperfiltration of diabetes. Am J Physiol 254:F668–F676, 1988
  37. Ha H, Duham EW: Limited capacity for renal vasodilatation in anesthetized diabetic rats. Am J Physiol 252:H845–H855, 1987
  38. Bank N, Lahorra AG, Aynedjian HS, Schlondorff D: Vaso-regulatory hormones and the hyperfiltration of diabetes. Am J Physiol 254:F202–F209, 1988 | PubMed | ChemPort |
  39. Reineck HJ, Kreisberg JI: Renal vascular response to angiotensin II in rats with streptozotocin-induced diabetes mellitus. (abstract) Kidney Int 23:247, 1983
  40. Sarubbi D, McGiff JC, Quilley J: Renal vascular responses and eicosanoid release in diabetic rats. Am J Physiol 257:F762–F768, 1989
  41. Craven PA, Melhem MF, DeRubertis FR: Thromboxane in the pathogenesis of glomerular injury in diabetes. Kidney Int 42:937–946, 1992

Extra navigation

.
ADVERTISEMENT